



ACCOMPLISHMENTS

TWO international multi-center studies are ongoing: 1) International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (**InVITE Study**); and 2) A phase IIIB/IV randomized open-label with pharmaco-enhanced darunavir vs dolutegravir with predetermined nucleosides vs recommended standard of care antiretroviral regimens in patients with HIV infection who failed recommended first line therapy (**D2EFT Study**).

GOAL 1: Generate knowledge, disseminate results, and promote utilization of research findings.

PUBLICATIONS

- ❖ **Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial**, Lancet, January 2022.
- ❖ **Coinfection with SARS-CoV-2 and dengue virus: a case report highlighting diagnostic challenges**, Frontiers in Tropical Diseases, February 2022.
- ❖ **Epidemiology of community-acquired pneumonia among hospitalized children in Indonesia: a multicenter, prospective study**, BMJ Open, June 2022.
- ❖ **Mild SARS-CoV-2 Reinfection with Delta Variant: First Case Report from Indonesia**, Frontiers in Medicine, July 2022.
- ❖ **The Characteristics of Bacteremia among Patients with Acute Febrile Illness Requiring Hospitalization in Indonesia**, PLOS ONE, September 2022.
- ❖ **Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)**, PLOS ONE, September 2022.
- ❖ **Characteristics of Drug-Sensitive and Drug-Resistant Tuberculosis Cases Among Adults at Tuberculosis Referral Hospitals in Indonesia**, American Journal of Tropical Medicine and Hygiene, October 2022.
- ❖ **Performance of Xpert TB/RIF and Sputum Microscopy Compared to Sputum Culture for Diagnosis of Tuberculosis in Seven Indonesian Hospitals**, Frontiers in Medicine, December 2022.

STUDIES

- **D2EFT** - Clinical Trial, study ongoing.
Total randomized: **46**.
4 hospitals study sites.
- **InVITE** - Observational, study ongoing.
Total enrolled: **700**.
3 hospitals study sites.
- **ORCHID** - Observational, study almost completed. Total enrolled: **185**.
2 hospitals study sites.
- **PROACTIVE** - Observational, study ongoing
Total enrolled: **4,336**.
19 hospitals study sites.

POSTER PRESENTATIONS

- **ASTMH Annual Meeting, 30 Oct- 3 Nov 2022:**
"The Characteristics of Bacteremia among Patients with Acute Febrile Illness Requiring Hospitalization in Indonesia", and
"Assessment of Schistosoma japonicum Infection in Endemic Areas of Central Sulawesi, Indonesia, after Mass Drug Administration Program".
- **ISID Congress, 17-20 November 2022:**
"HIV viral suppression rate at enrolment, status at one year and associated factors to non-suppression among outpatient adults at 19 hospitals in Indonesia".

COVID-19 WEBINAR SERIES

Lessons learned from two years of the pandemic. Are we getting closer to the finish line? The 4th Webinar, 21 May 2022.

GOAL 2: Build INA-RESPOND as a sustainable research network capable of conducting excellent clinical.

COLLABORATIONS

- National HIV/AIDS Program
- National TB Program
- National Vector and Zoonosis Disease Program
- NIAID/NIH
- INSIGHT
- NCI/NIH
- US-CDC
- RePORT
- The Kirby Institute/UNSW
- Columbia University/GAPP
- WHO
- PT Prodia Diacro Laboratories
- PT Ganesha Aggies Jaya

TRAININGS

- GCP Training
- Data Management Training
- Laboratory Training
- Clinical Research Protocol Writing Training
- Scientific Writing Support for Sites
- Studies-specific Training and Refresher Training for Sites
- NIAID HIV Lecture Series
- Clinical Research Project Management Training
- INA-RESPOND SOPs Training
- Studies SOPs Training
- NIH Information & Security Privacy Awareness Refresh Training
- Orientation and Training for new hires

STUDIES SITES

- Site 510 - Hasan Sadikin Hospital
- Site 520 - Sanglah Hospital
- Site 521 - Udayana University Hospital
- Site 530 - Cipto Mangunkusumo Hospital
- Site 540 - Sulianti Saroso Hospital
- Site 550 - Wahidin Sudirohusodo Hospital
- Site 560 - Kariadi Hospital
- Site 570 - Soetomo Hospital
- Site 580 - Sardjito Hospital
- Site 590 - Persahabatan Hospital
- Site 600 - Adam Malik Hospital
- Site 610 - Tangerang Hospital
- Site 630 - Ansari Saleh Hospital
- Site 640 - Saint Carolus Hospital
- Site 650 - Budi Kemuliaan Batam Hospital
- Site 660 - Wahab Sjahranie Hospital
- Site 670 - Zainoel Abidin Hospital
- Site 680 - Soedarso Hospital
- Site 690 - Abepura Hospital
- Site 700 - TC Hillers Hospital

These sites participated and served as prime resources in the INA-RESPOND clinical studies

GOAL 3: Achieve organizational excellence.

OPERATIONS

INA-RESPOND established and enhanced network capabilities in the following areas:

- Ten Core Sites and additional Study-Specific Sites as needed: *serve as main core sites and/or study specific sites.*
- Reference Laboratory: *serve as the central reference laboratory for the Network.*
- Data Management Center: *serve as the main data management center of the Network.*
- Policies and SOPs: *outlines the essential requirements of the Network and ensure compliance with the ICH-GCP.*
- IT Operations Infrastructure and Network: *main IT operations for the Network.*
- Website: *maintenance of the Network website to share information with partnering sites and potential collaborators.*
- Monthly Newsletter: *monthly information on the ongoing Network activities and articles.*
- Scientific Manuscript Writing Guidebook.



VISION

Become the premier research network in the region providing evidence to inform policy making, minimize the impact of infectious diseases and improve human well-being.

MISSION

Improve the health of the people of Indonesia and benefit the international community, by conducting high-quality infectious disease research through a collaborative, sustainable, and well-recognized research network.

VALUES

- Beneficial and Responsive to the research needs of Indonesia and the international community
- Innovative in designing, implementing, and integrating research in a healthcare setting
- Goal-Oriented to achieve the mission of the network
- High-Quality in conducting scientifically sound and ethical infectious disease research
- Trust and Teamwork with respect, transparency, communication, collaboration, and shared responsibility

www.ina-respond.net